Morgan Rouprêt, ESOU22: Impact of Immune Checkpoint Inhibitors on the Treatment of Bladder, Prostate and Kidney Cancer

ESMO 2023 brought forth some practice-changing data in the field of non-prostate genitourinary cancer. To understand these, as well as the other key trials and highlights from the meeting, we engaged in a conversation with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros […]

As part the Young Oncologists session, at ESMO 2023, Prof. Petros Grivas (Clinical Director of the Genitourinary Cancer Program, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA) and colleagues, spent time speaking with medial students and early-career physicians about developing a successful career in medial oncology.  For those that were unable to attend the […]

The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]